FDA Updates List of Off-Patent, Off-Exclusivity Drugs Without  Generic Competition

Public health researchers call for new measures to protect pharmaceutical supply chain

Babies with a rare, severe form of epilepsy depend on this drug. The maker stopped selling it.

A Patient‐Centric Model for Discontinuation of a Single‐Sourced Approved Drug

Discontinuation of US-labeled PEGANONE 250 mg Tablets (ethotoin tablets, USP)

This Old Drug Was Free. Now It’s $109,500 a Year

Senator Rosen introduced S.2257 Expanding Access to Affordable Prescription Drugs and Medical Devices Act

 Tutela Pharmaceuticals Inc. was selected to deliver a company presentation at 2021 BIO Digital, the premier biotech event.

Tutela Pharmaceuticals Inc. has executed an Exclusive License Agreement with Astellas Pharma Inc. for worldwide rights to FK1706, an FKBP (FK506 binding protein) ligand, for the treatment, prevention, or palliation of any human diseases or disorders. This license will allow Tutela to expedite the development of FK1706 for treatment of coronavirus infections in combination with virus-targeted antivirals. Astellas had previously studied the use of FK1706 in clinical trials for the potential treatment of neuropathy.

Tutela’s PCT patent application entitled “Methods of treating coronavirus infections by co-administering an FKBP ligand and an antiviral agent” was published on February 17, 2022.